Frontiers in public health · 2024
Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeitoun Abeer, Ibrahim Aya, Reda El Sayed Sarah, Hobeika Eva, Karam Rita
Аннотация
BACKGROUND: A national Oral Cholera Vaccine (OCV) Euvichol-Plus® campaign was launched in Lebanon, in response to the first outbreak in three decades, recorded in October 2022. The OCV vaccination campaign was carried out between November 2022 and February 2023. This study aims to cover adverse events reports, received at the Lebanese National Pharmacovigilance Program's (LNPVP) passive surveillance system.
METHODS: Case reports were extracted from the LNPVP's database. SPSS software was used to perform statistical analysis, with categorical variables compared using Pearson's χ 2 test. A descriptive analysis was performed based on age, gender, vaccine administered, and adverse event(s) associated with the administered vaccine.
RESULTS: A total of 115 Adverse Events Following Immunization (AEFIs) were reported, which corresponded to 46 case reports. The top three reported AEFIs were fever (39.13%), diarrhea (30.43%), and vomiting (30.43%). Reported cases were non-serious (82.6%). The highest proportion of Individual Case Safety Reports (ICSRs) received is attributed to females (56.5%), and the age category of 2 and 11 years old (41.3%). Reporters' age range was 1-74 years old.
CONCLUSION: Monitoring AEFIs through the cholera outbreak's emergency campaign favors the safety profile of OCV.
METHODS: Case reports were extracted from the LNPVP's database. SPSS software was used to perform statistical analysis, with categorical variables compared using Pearson's χ 2 test. A descriptive analysis was performed based on age, gender, vaccine administered, and adverse event(s) associated with the administered vaccine.
RESULTS: A total of 115 Adverse Events Following Immunization (AEFIs) were reported, which corresponded to 46 case reports. The top three reported AEFIs were fever (39.13%), diarrhea (30.43%), and vomiting (30.43%). Reported cases were non-serious (82.6%). The highest proportion of Individual Case Safety Reports (ICSRs) received is attributed to females (56.5%), and the age category of 2 and 11 years old (41.3%). Reporters' age range was 1-74 years old.
CONCLUSION: Monitoring AEFIs through the cholera outbreak's emergency campaign favors the safety profile of OCV.